Redwood Investments LLC Purchases 8,787 Shares of Enovis Co. (NYSE:ENOV)

Redwood Investments LLC lifted its position in Enovis Co. (NYSE:ENOV - Free Report) by 39.5% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 31,043 shares of the company's stock after purchasing an additional 8,787 shares during the quarter. Redwood Investments LLC owned about 0.05% of Enovis worth $1,362,000 at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in ENOV. Quadrant Capital Group LLC increased its stake in Enovis by 53.0% in the fourth quarter. Quadrant Capital Group LLC now owns 690 shares of the company's stock valued at $30,000 after acquiring an additional 239 shares during the last quarter. Amalgamated Bank increased its stake in Enovis by 1.0% in the fourth quarter. Amalgamated Bank now owns 25,887 shares of the company's stock valued at $1,136,000 after acquiring an additional 264 shares during the last quarter. Pinnacle Bancorp Inc. increased its stake in Enovis by 54.5% in the fourth quarter. Pinnacle Bancorp Inc. now owns 850 shares of the company's stock valued at $37,000 after acquiring an additional 300 shares during the last quarter. Arizona State Retirement System increased its stake in Enovis by 2.6% in the fourth quarter. Arizona State Retirement System now owns 16,208 shares of the company's stock valued at $711,000 after acquiring an additional 414 shares during the last quarter. Finally, UMB Bank n.a. increased its stake in Enovis by 128.2% in the fourth quarter. UMB Bank n.a. now owns 778 shares of the company's stock valued at $34,000 after acquiring an additional 437 shares during the last quarter. Institutional investors own 98.45% of the company's stock.

Analyst Ratings Changes

ENOV has been the subject of several analyst reports. Canaccord Genuity Group cut their price target on shares of Enovis from $75.00 to $70.00 and set a "buy" rating for the company in a research report on Wednesday. JMP Securities cut their price target on shares of Enovis from $62.00 to $55.00 and set a "market outperform" rating for the company in a research report on Friday, May 9th. Finally, Needham & Company LLC dropped their target price on shares of Enovis from $64.00 to $57.00 and set a "buy" rating for the company in a report on Friday, May 9th. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $58.00.

Enovis Stock Performance

NYSE:ENOV traded up $0.37 during trading hours on Friday, reaching $36.10. The company had a trading volume of 539,929 shares, compared to its average volume of 780,866. The company has a current ratio of 2.27, a quick ratio of 1.12 and a debt-to-equity ratio of 0.40. Enovis Co. has a 52 week low of $29.32 and a 52 week high of $52.76. The firm has a market cap of $2.06 billion, a price-to-earnings ratio of -16.49 and a beta of 1.79. The firm's 50 day moving average price is $35.15 and its 200-day moving average price is $41.42.

Enovis (NYSE:ENOV - Get Free Report) last issued its quarterly earnings data on Thursday, May 8th. The company reported $0.81 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.74 by $0.07. Enovis had a negative net margin of 5.95% and a positive return on equity of 4.39%. The firm had revenue of $558.83 million during the quarter, compared to the consensus estimate of $558.80 million. During the same quarter in the previous year, the firm posted $0.50 EPS. The company's revenue for the quarter was up 8.2% compared to the same quarter last year. On average, analysts forecast that Enovis Co. will post 2.79 EPS for the current year.

About Enovis

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.